Immunotherapy provides long-term survival benefits for more patients with esophageal cancer

China's annual new esophageal cancer about 246,000 cases, 188,000 deaths, in order to promote China's esophageal cancer field authoritative experts and multidisciplinary doctors to cooperate and exchange, leading China's comprehensive diagnosis and treatment level of esophageal cancer into a new stage, by The Beijing University Cancer Hospital deputy
, Beijing Cancer Society rotating director Professor Shen Lin as director of the
"Beijing Cancer Prevention Society Esophageal Cancer Professional
Conference" was officially established in Beijing on September 6. Members of the adm committee come from More than 70 hospitals in China, including Peking University Oncology Hospital, China Medical
Oncology Hospital and Hebei Medical University Fourth Hospital, covering clinicians and scholars engaged in basic medical research in the fields of internal medicine, surgery, radiotherapy, imaging and pathology.
Shen Lin, China's esophageal cancer incidence and death accounted for more than half of the world, china's middle and late esophageal cancer patients five-year survival rate of less than 20%. The reason is on the one hand, because the early symptoms of esophageal cancer hidden, screening is difficult, resulting in 70% of esophageal cancer patients diagnosed is late-stage, treatment is difficult, treatment methods are limited and the patient's prognostic difference, especially late-stage patients due to high tumor load often have lost the opportunity to cure surgery. On the other hand, because of China's esophageal cancer in the population, high-risk factors and pathological types are significant differences in Western countries, the Western esophageal adenocarcinoma is high, and more than 90% of patients in China are esophageal squamous cancer.
Professor Shen Lin said that compared with other types of cancer, there has been no breakthrough in treatment and survival improvement of esophageal cancer for decades, and that in recent years the success of immunotherapy in the treatment of esophageal cancer has broken through this "bottleneck", immunotherapy combined chemotherapy or other therapies will provide long-term survival benefits for more patients with esophageal cancer.the
study showed that the median total survival time of patients with immunotherapy Paboliju monotherapy PD-L1 expression-positive esophageal squamous cancer increased from 5.4 months to 12 months, the risk of death decreased by 62%, and patients who survived for more than one year were three times more effective, long-term survival benefits and safety significantly better than traditional standard treatments and Chinese groups benefited better. In 2019, the world's first immunotherapy drug for esophageal cancer, Paboliju monoantigen, was approved in the United States, and in June 2020 Paboliju monoantigen was approved in China for the treatment of patients with second-line advanced esophageal squamous cancer.
"Immune therapy has allowed us to see the dawn of treatment of esophageal squamous cancer, and the success of Paboli Pearl single anti-immune therapy in second-line treatment of esophageal cancer is encouraging, and more patients with esophageal cancer may benefit from it in the future if it is used for first-line treatment or even earlier, " said Professor Yu Qingxia, consultant to the adjournment committee and director of the oncology department of Zhengzhou University's First Affiliated Hospital. Professor
Shen Lin said: "Since the immune environment of primary treatment of esophageal cancer is more immune, we are looking forward to a better outcome for Pabliju monoantigen in the first line." At the upcoming annual meeting of the European Society of Oncology (ESMO), the positive results of the test of Pabliju single anti-combination chemotherapy for first-line treatment of esophageal cancer will be announced, which will be the world's first clinical trial of PD-1 inhibitor combination chemotherapy comparing chemotherapy options in first-line esophageal cancer treatment, and as one of the leading researchers, I believe the results of the forthcoming first-line treatment are expected to rewrite the pattern of esophageal cancer treatment. "